Treatments

Clinical studies identifies a key role of CB1 and CB2 receptors in the development of Osteoporosis

Osteosporosis

Cannabinoids and the skeleton: from marijuana to reversal of bone loss. (2009)

Abstract

The active component of marijuana, Delta(9)-tetrahydrocannabinol, activates the CB1 and CB2 cannabinoid receptors, thus mimicking the action of endogenous cannabinoids. CB1 is predominantly neuronal and mediates the cannabinoid psychotropic effects. CB2 is predominantly expressed in peripheral tissues, mainly in pathological conditions. So far the main endocannabinoids, anandamide and 2-arachidonoylglycerol, have been found in bone at ‘brain’ levels[…]

Author Information

Bab I, Zimmer A, Melamed E.

Bone Laboratory, the Hebrew University of Jerusalem, Jerusalem, Israel. babi@cc.huji.ac.il

Cannabinoids in health and disease. (2007)

Abstract

Cannabis sativa L. preparations have been used in medicine for millennia. However, concern over the dangers of abuse led to the banning of the medicinal use of marijuana in most countries in the 1930s. Only recently, marijuana and individual natural and synthetic cannabinoid receptor agonists and antagonists, as well as chemically related compounds, whose mechanism of action is still obscure, have come back to being considered of therapeutic value[…]

Author Information

Kogan NM, Mechoulam R.

Medicinal Chemistry and Natural Products Dept, Pharmacy School, Ein-Kerem Medical Campus, the Hebrew University of Jerusalem, Israel.

The endocannabinoid system as an emerging target of pharmacotherapy. (2006)

Abstract

The recent identification of cannabinoid receptors and their endogenous lipid ligands has triggered an exponential growth of studies exploring the endocannabinoid system and its regulatory functions in health and disease. Such studies have been greatly facilitated by the introduction of selective cannabinoid receptor antagonists and inhibitors of endocannabinoid metabolism and transport, as well as mice deficient in cannabinoid receptors or the endocannabinoid-degrading enzyme fatty acid amidohydrolase[…]

Author Information

Pacher P, Bátkai S, Kunos G.

Laboratory of Physiological Studies, National Institute of Alcohol Abuse and Alcoholism, National Institutes of Health, 5625 Fishers Lane, Room 2S-24, Bethesda, MD 20892-9413, USA.

Treatments
_